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Abstract 
Over the last decade a convergent body of evidence has emerged from 
epidemiology, animal experiments and clinical trials which links low vitamin D status 
with a range of adverse neuropsychiatric outcomes. This research demonstrates that 
the timing of exposure to low vitamin D influences the nature of brain phenotypes, as 
exposures during gestation versus adulthood result in different phenotypes. With 
respect to early life exposures, there is robust evidence from rodent experiments 
indicating that transient Developmental Vitamin D (DVD) deficiency is associated 
with changes in brain structure, neurochemistry, gene and protein expression and 
behavior. In particular, DVD deficiency is associated with alterations in the 
dopaminergic neurotransmitter systems. In contrast, recently published animal 
experiments indicate that Adult Vitamin D (AVD) deficiency is associated with more 
subtle neurochemical and behavioural phenotypes. This paper explores key issues 
that need to be addressed in future research. There is a need to define the timing 
and duration of the ‘critical window’ during which low vitamin D status is associated 
with differential and adverse brain outcomes.  We discuss the role for ‘two-hit 
hypotheses’, which propose that adult vitamin D deficiency leaves the brain more 
vulnerable to secondary adverse exposures, and thus may exacerbate disease 
progression. Finally, we explore the evidence implicating a role for vitamin D in rapid, 
non-genomic mechanisms that may involve L-type calcium channels and brain 
function.    
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1. Introduction 
Over the last decade there has been a marked increase in research exploring the 
role of vitamin D in the brain. This research was inspired by the pioneering work of 
Stumpf [1], Wion and Garcion [2, 3]. In a landmark study by Eyles and colleagues, 
the distribution of the vitamin D receptor (VDR) and the key rate limiting enzyme 
involved in the production of 1,25 dihydroxyvitamin D (1,25(OH)2D), was mapped in 
the adult brain [4]. Of particular interest, the distribution of VDR in certain brain 
regions suggested that vitamin D may influence particular neurotransmitters and 
cortical function. For example, expression of the VDR was identified in the 
hippocampus and prefrontal cortex – brain regions required for learning and 
memory, and executive control, and implicated in a range of neuropsychiatric 
disorders. VDR expression appeared most prominent in the substantia nigra, a 
region rich in dopaminergic neurons. Subsequent research has provided robust 
evidence linking vitamin D related mechanisms and dopaminergic neurotransmission 
[5-8].  
 
A growing body of epidemiological research has also linked vitamin D status and risk 
of brain disorders. The field has moved on from the early ecological studies (e.g 
those based on latitude gradients and seasonal variations), to stronger analytic 
methods that have directly measured vitamin D status. These studies have included 
(a) cross-sectional studies based on case-control samples, or (b) longitudinal cohort 
studies linking baseline vitamin D status and later incidence brain disorders. With 
respect to brain disorders, multiple sclerosis has long been linked to vitamin D [9-11]. 
Other brain disorders of interest to vitamin D related epidemiology research include 
(a) dementia and cognitive function [12-14], (b) Parkinson’s disease [15], (c) 
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depression [16],  (d) schizophrenia or psychosis [17-20] and (e) autism [21, 22]. The 
results of these studies are by no means consistent, but provide sufficient evidence 
to justify ongoing studies – the evidence of these studies is covered more 
extensively in reviews by Deluca and colleagues[23] and Groves and colleagues 
[24]. In the current article, we take a more forward-looking perspective and suggest 
key areas that are needed to inform future research.  
 
2. Are there ‘critical windows’ when low vitamin D differentially impacts on 
brain function? 
In keeping with the well known pro-differentiating and anti-proliferating properties of 
1,25(OH)2D [25], there is robust and consistent evidence from in vitro studies and 
animal experiments that low vitamin D alters brain development [26]. Based on a 
series of rodent experiments, it is now clear that the behavioural and neurochemical 
correlates of Adult Vitamin D (AVD) deficiency are distinct from those associated 
with Developmental Vitamin D (DVD) deficiency [27, 28]. Thus, timing is critical – 
exposure to low vitamin D during brain development will have different 
consequences on brain function compared to exposure to low vitamin D during 
adulthood. However, we do not understand the nature of the relationship between 
the timing and duration of exposure to low vitamin D versus the risk of different brain 
phenotypes.  
 
Future animal studies need to be extended and refined in order to examine the 
impact of maternal vitamin D deficiency across all stages of pre- and early postnatal 
brain development. We have little information on the precise timing of the critical 
window in rodent studies and what implications these findings have for human brain 
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function [29]. After switching an adult rodent to a vitamin D deplete diet, it still takes 4 
to 6 weeks to induce 25 hydroxyvitamin D (25OHD) deficiency. In contrast, after 
switching back to a standard rodent (vitamin D replete) diet, 25OHD concentrations 
can normalize over 7 to 10 days. By carefully increasing the duration of maternal 
vitamin D deficiency, it will be feasible to assess overlapping developmental periods 
and thereby help define the key vitamin D-sensitive developmental windows for the 
developing brain. The second key issue to consider relates to the fact that the 
gestational period in the rat and mouse is far shorter than in humans and the CNS in 
rodents is far less developed at birth. With respect to comparing developmental 
neurobiological stages between rat and humans, the most recent recommendation is 
that in the rat, the periods of (a) conception to embryonic day 18, and (b) embryonic 
day 18 to post-natal day 11, best reflect human brain growth during the first and 
second trimesters respectively [30]. By inference, rats after post-natal day 11 are 
entering the equivalent of the third trimester of human brain growth. This suggests 
that rodent offspring resulting from the standard DVD deficiency experimental model 
may only be vitamin D deficient for the equivalent of the first and most of the second 
trimester of human CNS development. By prolonging DVD-deficiency until weaning 
(post-natal day 21), this model covers the period of brain development equivalent to 
the third trimester of human development.  
 
Animals that arise from dams that are vitamin D deplete until birth (DVD-deplete 
animals) have increased lateral ventricle volume at birth [31]. However if the 
reintroduction of vitamin D is delayed until weaning, a persistent increase in lateral 
ventricle volume can be shown in the adult offspring [32]. This finding is important as 
it suggests that although the absence of gestational vitamin D leads to abnormal 
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ventricle formation, there is a postnatal window when the reintroduction of vitamin D 
can partially ‘rescue’ this phenotype. Animal models that extend vitamin D deficiency 
beyond gestation and weaning induce rickets, which confounds the interpretation of 
many behavioural phenotypes [33]. 
 
In humans, it is also clear that a great deal of brain development happens in the first 
few years of life. Epidemiological and imaging studies indicate that peri-pubertal and 
adolescence stages are also implicated in disorders such as schizophrenia [34, 35]. 
It is feasible that different brain disorders are associated with different critical 
windows. Neonatal vitamin D status is linked to the risk of schizophrenia [36] but not 
multiple sclerosis [37]. Longitudinal birth cohort studies, with repeated measures of 
vitamin D status at multiple time points, may help define the timing and duration of 
the critical window [38, 39].   
 
 
3. Adult vitamin D deficiency and brain function – does vitamin D 
deficiency leave the brain vulnerable to future insults? 
 
As mentioned above, the impact of low vitamin D intake on adult brain function is 
very different to that in developmental models. The findings based on AVD rat and 
mouse models tend to be relatively subtle, and vary according to species and strain 
[27, 28], while some findings are more consistent than others. For example, mouse 
AVD deficiency studies have identified significantly reduced glutamic acid 
decarboxylase (GAD) 65/67 levels (key enzymes in gamma-aminobutyric acid 
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(GABA)-ergic interneurons) and decreased levels of glutamate and glutamine in 
brain tissue [27].  
 
There is convergent evidence from animal experimental studies to suggest that 
vitamin D status may be important in how the brain recovers from a neurological 
insult. For example, in vitro studies indicate that optimal vitamin D status is 
‘neuroprotective’ and pretreatment with 1,25(OH)2D can ameliorate the impact of a 
range of experimental lesions [40-45].  In a key study by Brewer and colleague [46], 
it was found that 1,25(OH)2D protected rat primary hippocampal cultures from 
excitotoxic insults (i.e. glycine and N-methyl-D-aspartate, NMDA). Patch clamp 
studies found that, under certain conditions, L type voltage dependent calcium 
currents were reduced following incubation with 1,25(OH)2D. Quantitative real-time 
PCR demonstrated that incubation with 1,25(OH)2D reduced mRNA expression of 
genes encoding for subunits of these channels (e.g. CACNA1C and CACNA1D).  
This neuroprotective capacity has lead researchers to develop ‘two hit’ animal 
models, based on the hypothesis that low vitamin D status exacerbates the impact of 
a lesion and/or reduces the ability of the organism to recover.  Using an AVD 
deficiency model (as the first hit), and a model related to cerebrovascular accidents 
(as the second hit), Balden and colleagues [47] found that vitamin D deficiency was 
associated with significantly increased infarct volume and reduced behavioural 
recovery. For example, compared to animals with normal vitamin D concentration, 
AVD-deficient rats had a 20% increase of infarct volume in the striatum and a 40% 
increase in cortical volume 5 days after ischemia induced by middle cerebral artery 
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occlusion. These findings provide strong evidence that low vitamin D concentrations 
exacerbate recovery from brain lesions.  
 
Convergent evidence in support of this hypothesis has been provided by a 
randomized clinical trial of vitamin D supplementation in Parkinson’s disease [48].  In 
this study, those on placebo had a steady worsening on neurological outcomes. In 
contrast, those on vitamin D supplements had no change in Parkinson disease-
related outcomes over the year. The results strongly suggest that low vitamin D 
status can influence disease progression.  These findings have led us to speculate 
that adult vitamin D deficiency could exacerbate the progression of a wide range of 
other brain disorders such as multiple sclerosis, dementia and depression [49].  
 
If low vitamin D status delays recovery and/or worsens clinical symptoms, then it is 
understandable how low vitamin D may be identified as a candidate risk factor in 
case-control studies (i.e. affected individuals are drawn from prevalent cases, often 
those in contact with clinical services).  In summary, low vitamin D status during 
adulthood may be associated with worse health outcomes and disease burden, but 
via more complex mechanisms involving comorbidity with other disorders.  
 
4. What is the role of rapid non-genomic vitamin D-related mechanisms in 
the brain? 
Early work based on the DVD deficiency model suggested that vitamin D deficiency 
altered brain development via mechanisms such as altered neuronal proliferation, 
differentiation and apoptosis. Steroid hormones in general, including vitamin D, are 
known to influence the cell cycle and differentiation via nuclear receptors and 
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genomic response elements [50] and there is evidence indicating that these 
mechanisms operate in the developing brain [31, 51, 52]. However it is less clear 
what roles non-genomic (or rapid) mechanisms may play in mediating the 
association between vitamin D and brain function. To date, most of the in vitro 
studies exploring the rapid non-genomic properties of 1,25(OH)2D have been carried 
out on non-neuronal tissue [53-56].  
 
Brewer and colleagues have already provided evidence linking 1,25(OH)2D and L-
type calcium channel (LTCC) [46]. There is now a solid body of evidence linking 
LTCC activity with 1,25(OH)2D  in non-neuronal cell types (e.g. skeletal muscle, 
osteoblast) [57, 58].  Patch-clamping studies and calcium imaging in transfected 
cells confirm that 1,25(OH)2D alters LTCC-mediated events [59, 60].   The influence 
of 1,25(OH)2D on adult neurogenesis in the hippocampal dentate gyrus is also 
contingent on LTCCs. Based on BrdU/NeuN studies in transgenic animals lacking 
the enzyme required to produce 1,25(OH)2D, the absence of 1,25(OH)2D was 
associated with a two fold increase in neurogenesis (in keeping with the well-known 
pro-differentiating and anti-proliferative properties of 1,25(OH)2D).  Additionally, the 
absence of 1,25(OH)2D can lead to the increased expression of LTCCs, which can 
subsequently be blocked by the LTCCs antagonist nifedipine [61]. Furthermore, 
several studies have provided support for the links between 1,25(OH)2D, LTCC and 
neuronal function, as well as the association between 1,25(OH)2D concentration and 
the expression of CACNA1C transcripts [62-66].  
 
In summary, there is now strong evidence indicating that 1,25(OH)2D impacts on 
LTCC function, and that these processes are highly relevant to neuronal function. 
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Indeed, the modulation of calcium entry into neural cells by the 1,25(OH)2D could 
influence a wide range of neuronal functions, such as maturation of the nervous 
system during development, and/or neuroprotection during adulthood [67, 68]. 
 
In 2013 a major collaborative study from the Psychiatric Genomics Consortium was 
published in the Lancet [69].  The study combined approximately 30,000 cases of 
autism, attention deficit disorder, bipolar disorder, major depressive disorder and 
schizophrenia and 28,000 controls. Across all disorders, SNPs in two LTCC genes 
were identified that met genome-wide significance (in CACNA1C and CACNB2). 
Pathway analysis supported a role for genes involved in calcium channel signalling 
genes for all five disorders. These findings provide further evidence of the 
importance of these pathways in neuropsychiatric disorders [70, 71] and possibly in 
Alzheimer’s disease [72].  
 
5. Future directions 
We have learnt a great deal about vitamin D and the brain in the last 10 years. In 
particular, rodent experiments have provided a solid experimental framework to 
examine the neurobiological correlates of vitamin D status. Key discoveries include 
the robust links between DVD deficiency and altered brain development in the 
rodent. It remains to be seen if low vitamin D during development is associated with 
clinical disorders, but there is emerging evidence linking low neonatal 25OHD 
concentrations and an increased risk of schizophrenia [20].   
 
In the adult brain, there is emerging literature suggesting that low vitamin D status 
may exacerbate brain lesions (i.e. a two-hit hypothesis). Key gaps in the literature 
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related to the timing and duration of the critical window throughout life when low 
vitamin D may have a differential impact on disease outcomes. Furthermore, the 
links between vitamin D and LTCC provide tantalizing clues to guide future research. 
Curiously, estrogen directly potentiates LTCC via non-genomic (and estrogen 
receptor independent) mechanisms [73]. This raises the potential that a wider class 
of steroid and seco-steroids may also operate via these mechanisms. These are 
tractable research questions as modern electrophysiology and calcium imaging 
techniques will be able to further explore and dissect these research questions. Of 
course, clues from basic neuroscience need to cross-talk with epidemiology (i.e. 
translational epidemiology) [74]. If convergent evidence does link low vitamin D 
status with particular brain disorders, then clinical trials are needed to confirm the 
association, and inform future health practices. Even if low vitamin D is ultimately 
shown to cause only a small fraction of the burden of neuropsychiatric disorders, 
because vitamin D supplementation is safe, cheap and publically acceptable, these 
finding could have important implications for public health.  
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